ZM306416 50mg | ≥99%
CSNpharm
ZM-306416 is an inhibitor of VEGFR (Flk-1 or KDR) and Flt with IC50 of 100 nM and 2 μM.
More Information Supplier PageZM306416
Search Results
ZM306416 5mg | ≥99%
CSNpharm
ZM-306416 is an inhibitor of VEGFR (Flk-1 or KDR) and Flt with IC50 of 100 nM and 2 μM.
More Information Supplier PageZM306416
GSK3787 50mg | ≥99%
CSNpharm
GSK3787 selectively and irreversibly antagonizes PPARδ with pIC50 of 6.6 with no significant effect on hPPARα or hPPARγ.
More Information Supplier PageGSK3787
GSK3787 5mg | ≥99%
CSNpharm
GSK3787 selectively and irreversibly antagonizes PPARδ with pIC50 of 6.6 with no significant effect on hPPARα or hPPARγ.
More Information Supplier PageGSK3787
GSK3787 10mg | ≥99%
CSNpharm
GSK3787 selectively and irreversibly antagonizes PPARδ with pIC50 of 6.6 with no significant effect on hPPARα or hPPARγ.
More Information Supplier PageGSK3787
SU5416 50mg | ≥99%
CSNpharm
SU5416 is a selective VEGFR2 (Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
More Information Supplier PageSU5416
SU5416 5mg | ≥99%
CSNpharm
SU5416 is a selective VEGFR2 (Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
More Information Supplier PageSU5416
SU5416 100mg | ≥99%
CSNpharm
SU5416 is a selective VEGFR2 (Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
More Information Supplier PageSU5416
SU5416 10mg | ≥99%
CSNpharm
SU5416 is a selective VEGFR2 (Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
More Information Supplier PageSU5416
CPI-613 10mg | ≥98%
CSNpharm
CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.
More Information Supplier PageCPI-613
